Letterpenny
INVO merger with Naya creates NO value for Immune pharmaceuticals shareholders.
FURTHERMORE:
In the transaction, NAYA Biosciences' shareholders will receive 7.3333 shares of INVO for each share of NAYA Biosciences at closing, for a total of approximately 18,150,000 shares of INVO. Following the closing, the combined company is expected to operate under the name "NAYA Biosciences". INVO and NAYA shareholders will own approximately 12% and 88%, respectively, of the combined company. INVO insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of INVO's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
Cheers
